That position on the list places the actual peptide concentration somewhere between 0.001 and 0.1 percent by weight, with no encapsulation, no pH protection, and no delivery system that addresses any of the four failure modes above
PLoS One 3:e1376
Ferron M, Denis M, Persello A, Rathagirishnan R, Lauzier B (2018) Protein O-GlcNAcylation in cardiac pathologies: past, present, future
The clinical evidence so far is more reassuring than alarming for most people
These agents indirectly inhibit fluid volume increases by inhibiting angiotensin IIstimulated release of aldosterone
But more important than modifying risk factors, the GLP-1 RAs provide patients with type 2 diabetes on average a 14% relative risk reduction for major cardiovascular events, including: Cardiovascular death Heart attack Stroke Three GLP-1 RAs have been indicated by the FDA to reduce heart disease risk in people with type 2 diabetes who have or are at high risk for blockages of arteries of the heart, brain, and legs, also known as atherosclerotic cardiovascular disease (ASCVD): Dulaglutide, which is branded as Trulicity and is currently the only GLP-1 RA approved for cardiovascular disease risk reduction in patients with or without established ASCVD Liraglutide, which is branded as Victoza and was the first GLP-1 RA to show efficacy for heart benefits in a clinical trial Semaglutide, which has been increasingly prescribed off-label as a weight-loss medication under the brand name Ozempic Whereas we are still exploring the biological mechanisms of how GLP-1 Ras benefit the heart, the body of evidence we have at present is already revolutionizing the care of patients with type 2 diabetes
